Securities code: Shandong Sito Bio-Technology Co.Ltd(300583) abbreviation: Shandong Sito Bio-Technology Co.Ltd(300583) Announcement No.: 2022009 Shandong Sito Bio-Technology Co.Ltd(300583) announcement of resolutions of the board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The seventh meeting of the third board of directors of Shandong Sito Bio-Technology Co.Ltd(300583) (hereinafter referred to as “the company” or ” Shandong Sito Bio-Technology Co.Ltd(300583) “) was held at 10:00 a.m. on April 5, 2022 in the company’s conference room in a combination of on-site and communication. On April 2, 2022, all directors, supervisors and senior managers served the meeting notice and documents by e-mail. There were 7 directors who should attend the meeting, and 7 directors actually attended the meeting in person, including 3 independent directors. All supervisors and senior managers of the company attended the meeting as nonvoting delegates. The meeting was held in accordance with the company law of the people’s Republic of China and the articles of association.
The meeting was presided over by Mr. Mitch, chairman of the board of directors. After careful deliberation and voting, the following proposals were considered and adopted at the meeting:
The proposal on terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents was deliberated and adopted
Since the announcement of the plan of issuing A-Shares to specific objects in 2021, the board of directors, management and relevant intermediaries of the company have been actively promoting the work of issuing shares to specific objects. In view of the changes in the current capital market environment and financing opportunities, combined with the actual situation of the company, future development planning and other factors, after careful analysis and repeated communication with intermediaries, the company decided to terminate the issue of shares to specific objects and apply to Shenzhen stock exchange for withdrawal of relevant application documents. At present, all businesses of the company are operating normally. The termination of the issuance of shares to specific objects and the withdrawal of application documents will not have a significant adverse impact on the production and operation of the company, and there is no situation that damages the interests of the company and all shareholders, especially minority shareholders.
Voting results: 7 in favor, 0 against and 0 abstention, which was adopted.
The independent directors of the company have expressed their independent opinions and prior approval opinions on this proposal.
According to the authorization of the company’s first extraordinary general meeting of shareholders in 2021, this proposal does not need to be submitted to the general meeting of shareholders for deliberation. The company’s announcement on terminating the issue of A-Shares to specific objects in 2021 and withdrawing the application documents and the independent opinions and prior approval opinions of independent directors on this matter are detailed in the announcement published on cninfo.com, the gem information disclosure website designated by the CSRC（ http://www.cn.info.com.cn. ）。 It is hereby announced.
Documents for future reference: Shandong Sito Bio-Technology Co.Ltd(300583) the resolution of the seventh meeting of the third board of directors Shandong Sito Bio-Technology Co.Ltd(300583)
Board of directors
April 6, 2002
